Evidence map›Paper›PMID 31053612›Full record

ArticleThe Journal of experimental medicine2019

BCL6 corepressor contributes to Th17 cell formation by inhibiting Th17 fate suppressors.

Jessica A Kotov, Dmitri I Kotov, Jonathan L Linehan, Vivian J Bardwell, Micah D Gearhart, Marc K Jenkins

Abstract read
In one paragraph

Article in The Journal of experimental medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.2field-weighted citation impact, top 21% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 29 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Review
  7. NAR genomics and bioinformatics · 2023
    Article
  8. Article
  9. Review
  10. Review
  11. Article
  12. Article
  13. Dynamic Roles for IL-2-STAT5 Signaling in Effector and Regulatory CD4Journal of immunology (Baltimore, Md. : 1950) · 2020
    Review
  14. Article
  15. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jessica A KotovDepartment of Microbiology and Immunology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN.ORCID 0000-0002-1205-5178
Dmitri I KotovDepartment of Microbiology and Immunology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN.ORCID 0000-0001-7843-1503
Jonathan L LinehanDepartment of Cancer Immunology, Genentech, South San Francisco, CA.ORCID 0000-0003-2862-0511
Vivian J BardwellDevelopmental Biology Center, Masonic Cancer Center, and Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN.
Micah D GearhartDevelopmental Biology Center, Masonic Cancer Center, and Department of Genetics, Cell Biology, and Development, University of Minnesota, Minneapolis, MN gearh006@umn.edu.ORCID 0000-0002-9873-1930
Marc K JenkinsDepartment of Microbiology and Immunology, Center for Immunology, University of Minnesota Medical School, Minneapolis, MN jenki002@umn.edu.ORCID 0000-0001-8009-7655
University of Minnesota Medical Center · USUniversity of Minnesota · US

Funding

TRACKING CD4+ MEMORY T CELLS IN VIVOR01AI039614 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JENKINS, MARC KEVIN · 1996 to 2023
$8.7M
IMMUNOLOGY TRAINING PROGRAMT32AI007313 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Carla Rothlin · 1989 to 2026
$5.7M
COSTIMULATORY SIGNALS IN CD4+ T-CELL ACTIVATIONR01AI027998 · NIAID · UNIVERSITY OF MINNESOTA TWIN CITIES · PI JENKINS, MARC KEVIN · 1989 to 2022
$4.5M
Protective CD4+ T CellsR01AI103760 · NIAID · UNIVERSITY OF MINNESOTA · PI JENKINS, MARC KEVIN · 2013 to 2022
$4.2M
Costimulatory Signals in CD4+ T Cell ActivationR37AI027998 · NIAID · UNIVERSITY OF MINNESOTA · PI JENKINS, MARC KEVIN · 2008 to 2017
$3.7M
Minnesota Training Program in VirologyT32AI083196 · NIAID · UNIVERSITY OF MINNESOTA · PI Louis M Mansky · 2010 to 2026
$3.2M
Molecular Basis of Action of the Putative Oncogene BCL6R01CA071540 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI BARDWELL, VIVIAN J · 2002 to 2012
$3.0M
Control of Trophoblast Differentiation in Placental DevelopmentR01HD084459 · NICHD · UNIVERSITY OF MINNESOTA · PI BARDWELL, VIVIAN J · 2016 to 2020
$1.7M
The influence of Bcl-6 corepressor (BCOR) on Th17 cell developmentF31AI133716 · NIAID · UNIVERSITY OF MINNESOTA · PI KOTOV, JESSICA AMY · 2017 to 2018
$49k
NCI NIH HHS R01 CA071540NIAID NIH HHS F31 AI133716NIAID NIH HHS R01 AI027998NIAID NIH HHS R01 AI039614NIAID NIH HHS R01 AI103760NIAID NIH HHS R37 AI027998NIAID NIH HHS T32 AI007313NIAID NIH HHS T32 AI083196NICHD NIH HHS R01 HD084459
6 · The paper itself

Abstract

CD4

Indexed as

Cell LineageAnimalsCell DifferentiationCo-Repressor ProteinsCRISPR-Cas SystemsCytokinesF-Box ProteinsFemaleGene Expression RegulationJumonji Domain-Containing Histone DemethylasesLymphocyte SubsetsMaleMice, Inbred C57BLProto-Oncogene Proteins c-bcl-6Receptors, ChemokineRepressor ProteinsBcl6 protein, mouseBcor protein, mouseCo-Repressor ProteinsCytokinesF-Box ProteinsJumonji Domain-Containing Histone DemethylasesKdm2b protein, mouseProto-Oncogene Proteins c-bcl-6Receptors, ChemokineRepressor Proteins

Identifiers

PMID31053612
PMCPMC6547868
OpenAlexW2943604356

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.